Struggling to find Emgality at your pharmacy? Learn why this migraine prevention medication is hard to find in 2026 and what you can do about it.
You finally got your doctor to prescribe Emgality (Galcanezumab) for your migraines. You drove to the pharmacy, handed over the prescription — and they told you it's out of stock. No estimated date for when it's coming back. Sound familiar?
You're not imagining it. Emgality has been increasingly difficult to find at pharmacies across the country. Patients on migraine forums have been sharing their frustrations since late 2022, and the problem hasn't fully gone away. In this post, we'll break down exactly why Emgality is so hard to find and what steps you can take to get your medication.
Emgality is a brand-name prescription medication made by Eli Lilly and Company. Its generic name is Galcanezumab-gnlm. It belongs to a class of drugs called CGRP (calcitonin gene-related peptide) antagonists — a newer category of medications specifically designed for migraine prevention.
Emgality works by blocking CGRP, a protein in your brain that plays a major role in triggering migraines. By neutralizing CGRP, Emgality helps reduce how often migraines happen. It's FDA-approved for two uses:
Emgality is a self-administered injection given once a month using a prefilled pen or syringe. For migraine prevention, you start with a loading dose of 240 mg (two injections) followed by 120 mg monthly. For more details about how this medication works, check out our guide on how Emgality works.
There are several reasons Emgality can be difficult to find at your local pharmacy. Here are the main factors:
The American Society of Health-System Pharmacists (ASHP) has listed Emgality on its drug shortage list, citing increased demand as the primary reason. As more doctors prescribe CGRP inhibitors for migraine prevention — and as more patients learn about these newer treatments — the demand for Emgality has grown faster than Eli Lilly's production capacity.
Migraine affects about 39 million Americans, and CGRP inhibitors like Emgality represent a major breakthrough in treatment. It's no surprise that demand is high.
Emgality is a biologic medication — a complex, lab-grown antibody that requires cold-chain storage (refrigeration at 36°F to 46°F). Unlike a simple pill that every pharmacy stocks on the shelf, biologics like Emgality are often distributed through specialty pharmacies.
This means your regular retail pharmacy (CVS, Walgreens, Rite Aid) may not routinely keep Emgality in stock. They might need to special-order it from their wholesaler, which can take days or even weeks when supply is tight.
Most insurance plans require prior authorization before covering Emgality. Many also require step therapy — meaning you need to try and fail cheaper migraine medications first. This creates unpredictable demand at the pharmacy level, making it harder for pharmacists to know how much to keep on hand.
When a pharmacy doesn't know if or when a prior auth will be approved, they're less likely to stock Emgality proactively. Learn more about managing costs in our post on how to save money on Emgality.
As of 2026, there is no generic version or biosimilar of Emgality on the market. Galcanezumab is a monoclonal antibody, so it can't be replicated the way a simple chemical drug can. This means Eli Lilly is the sole manufacturer, and any production constraints directly affect supply for every patient.
If your pharmacy tells you Emgality is out of stock, don't panic. Here are some practical steps:
Don't assume that because one pharmacy is out, they all are. Call independent pharmacies, hospital pharmacies, and specialty pharmacies in your area. Independent pharmacies sometimes have better access to medications in short supply because they work with different wholesalers.
Medfinder helps you find pharmacies near you that have Emgality in stock right now. Instead of calling dozens of pharmacies yourself, let the tool do the work. You can also read our step-by-step guide on how to find Emgality in stock near you.
If Emgality is consistently unavailable, talk to your doctor about switching to another CGRP inhibitor. Options include Aimovig (Erenumab), Ajovy (Fremanezumab), Vyepti (Eptinezumab), or the oral option Qulipta (Atogepant). Read our full comparison in alternatives to Emgality.
Eli Lilly's support line (1-833-EMGALITY / 1-833-364-2548) can sometimes help locate pharmacies with stock or connect you with their specialty pharmacy network.
Since Emgality is a once-monthly injection, try to refill your prescription a week or more before your next dose is due. This gives you a buffer in case the pharmacy needs to order it.
Emgality has been a game-changer for many migraine patients, but finding it in stock can be a real challenge in 2026. The combination of high demand, specialty distribution, insurance barriers, and a sole manufacturer has created a perfect storm of availability issues.
The good news is that you have options. Use tools like Medfinder to check pharmacy stock, explore alternative CGRP medications with your doctor, and plan your refills ahead of time. For the latest on supply, check our Emgality shortage update for 2026.
You shouldn't have to go without your migraine medication. With a little persistence and the right tools, you can find Emgality — or a good alternative — that keeps your migraines under control.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
